Phathom Pharmaceuticals, Inc. (PHAT) Earnings Call Transcripts

Phathom Pharmaceuticals, Inc.'s Latest Earnings Call - June 9, 2026

In the second quarter of 2026, Phathom Pharmaceuticals reported a significant revenue increase, projecting 2026 revenues between $320 million and $345 million, up from $175 million in 2025. Management indicated that they expect Q3 2026 to be their first quarter of positive operating profit, marking a pivotal shift towards profitability. The company is focusing on deepening its penetration in the gastroenterology market, which is critical for future growth.

Reported metrics

Guidance from management

Management expects 2026 revenues between $320 million and $345 million and anticipates Q3 2026 will be their first quarter of positive operating profit.

What management said

And Paul, if I can just add one other thing we did beginning of the year. We look at our cap structure and then realize that we needed to have some modification in the cap structure to have more sustainable availability of funds. So we did that. We did a capital raise successful. We adjusted our debt. We paid down some part of the debt. And then now we have lowered the interest cost and now we have matched the repaym...

Last point on sort of the financial evolution for any investors who are new to the story, in addition to that capital restructuring and our growth from $175 million to the $320 million or $345 million this year, we have indicated to our investors that Q3 will be our first positive operating profit quarter. So we're converting profitability and 2027 will be a positive cash flow year. So we are at a fundamental inflect...

What analysts pressed on

Analysts are concerned about the pace of adoption in primary care and the potential impact of market access challenges on prescription growth. There are also questions regarding the sustainability of patient retention rates and how quickly the company can penetrate the broader GI market.

Main topics on the call

• Revenue Guidance Increase — Phathom has raised its revenue guidance for 2026 to between $320 million and $345 million, up from $175 million in 2025. Management stated, "we are on a steady growth trajectory for the product at a really nice pace."
• Positive Operating Profit Expected — Management indicated that Q3 2026 will be their first quarter of positive operating profit, stating, "we're converting profitability and 2027 will be a positive cash flow year." This signals a fundamental inflection poin...
• Focus on Gastroenterology Market — Phathom is concentrating its sales efforts on gastroenterology, with 60% to 70% of sales calls directed at GI practices. They reported that approximately 1 in 3 new-to-brand switches in top GI practices are to VOQUEZNA.
• Patient Satisfaction and Stickiness — Management noted high patient satisfaction with VOQUEZNA, with a cohort showing over 6 refills in 12 months. This suggests strong patient retention and potential for long-term revenue growth.

Read the full Phathom Pharmaceuticals, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 28 Phathom Pharmaceuticals, Inc. earnings call transcripts on record, spanning May 21, 2020 to July 30, 2026. Based on this history, Phathom Pharmaceuticals, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PHAT

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

28

First call

May 21, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly